Market Cap 305.92M
Revenue (ttm) 0.00
Net Income (ttm) -63.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.47
Volume 874,400
Avg Vol 1,935,822
Day's Range N/A - N/A
Shares Out 51.16M
Stochastic %K 35%
Beta 1.54
Analysts Strong Sell
Price Target $19.93

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 813 4701
Address:
6555 Carnegie Avenue, 4th Floor, Cleveland, United States
wemmmm
wemmmm Jun. 26 at 12:29 PM
$ABEO 6.20 today
1 · Reply
Paradise27
Paradise27 Jun. 25 at 10:56 PM
$ABEO Near term catalyst is a licensing agreement with Beacon Therapeutics for ABEO’s AAV204 for ophthalmology. Beacon’s 12 month review deadline is up and they’ll commit (or not) to the license at anytime now. If they accept then ABEO will allow Beacon to “take a worldwide, non-exclusive license to use AAV204 in connection with up to five gene or disease targets. Beacon will also have the right to use AAV204 for up to four additional nominated gene or disease targets subject to certain conditions. Under the agreement, Abeona will receive an upfront payment upon Beacon’s exercise of its option to license AAV204, with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204.” Up front payment estimated in the $30MIL range. https://investors.abeonatherapeutics.com/press-releases/detail/283/abeona-therapeutics-and-beacon-therapeutics-announce
0 · Reply
wemmmm
wemmmm Jun. 25 at 9:37 PM
$ABEO What are the upcoming catalysts? Thinking of takint sizeable position
2 · Reply
Paradise27
Paradise27 Jun. 25 at 7:34 PM
$ABEO @FinABAT Great find. $REGN Regeneron could easily scoop up ABEO for $18-20 per share if they wanted to which would include the PRV.
0 · Reply
JimiJoJeeter
JimiJoJeeter Jun. 25 at 7:33 PM
$ABEO Wow... an 111.4K buy spike.... nice!
0 · Reply
wemmmm
wemmmm Jun. 25 at 6:34 PM
$ABEO https://x.com/oraclenyse/status/1937940803323617746?s=46&t=PEWZbEPDlfCXIpORNZ-ynQ
0 · Reply
Paradise27
Paradise27 Jun. 25 at 5:54 PM
$ABEO Golden Cross on the chart bodes well for reversal to upward trend. MACD also rising with positive cross over most likely early next week. Buying pressure will build as ABEO heads towards profitability. Possible good news lurking from company near term. Shorts are done here.
0 · Reply
SeeKingProphet
SeeKingProphet Jun. 25 at 3:14 PM
$ABEO recent bear article from Sage Advisors being challenged by article in The Tencent is a buy signal IMHO. Whopping 9 days to cover could result in a squeeze soon 🌋
1 · Reply
creditgoo
creditgoo Jun. 25 at 2:41 PM
$ABEO interesting candle
0 · Reply
xelaxela
xelaxela Jun. 25 at 2:40 PM
$ABEO huge green candle!
0 · Reply
Latest News on ABEO
US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:06 AM EDT - 2 months ago

US FDA approves Abeona's skin disorder therapy


Pz-Cel Has Massive Potential For RDEB Patients

Apr 21, 2025, 10:00 AM EDT - 2 months ago

Pz-Cel Has Massive Potential For RDEB Patients


Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 3:20 PM EDT - 3 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript


US FDA declines to approve Abeona's skin disorder treatment

Apr 22, 2024, 4:31 PM EDT - 1 year ago

US FDA declines to approve Abeona's skin disorder treatment


Abeona Therapeutics Provides Regulatory Update on Pz-cel

Apr 22, 2024, 4:05 PM EDT - 1 year ago

Abeona Therapeutics Provides Regulatory Update on Pz-cel


Abeona Therapeutics Announces $50 Million Credit Facility

Jan 8, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Announces $50 Million Credit Facility


wemmmm
wemmmm Jun. 26 at 12:29 PM
$ABEO 6.20 today
1 · Reply
Paradise27
Paradise27 Jun. 25 at 10:56 PM
$ABEO Near term catalyst is a licensing agreement with Beacon Therapeutics for ABEO’s AAV204 for ophthalmology. Beacon’s 12 month review deadline is up and they’ll commit (or not) to the license at anytime now. If they accept then ABEO will allow Beacon to “take a worldwide, non-exclusive license to use AAV204 in connection with up to five gene or disease targets. Beacon will also have the right to use AAV204 for up to four additional nominated gene or disease targets subject to certain conditions. Under the agreement, Abeona will receive an upfront payment upon Beacon’s exercise of its option to license AAV204, with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204.” Up front payment estimated in the $30MIL range. https://investors.abeonatherapeutics.com/press-releases/detail/283/abeona-therapeutics-and-beacon-therapeutics-announce
0 · Reply
wemmmm
wemmmm Jun. 25 at 9:37 PM
$ABEO What are the upcoming catalysts? Thinking of takint sizeable position
2 · Reply
Paradise27
Paradise27 Jun. 25 at 7:34 PM
$ABEO @FinABAT Great find. $REGN Regeneron could easily scoop up ABEO for $18-20 per share if they wanted to which would include the PRV.
0 · Reply
JimiJoJeeter
JimiJoJeeter Jun. 25 at 7:33 PM
$ABEO Wow... an 111.4K buy spike.... nice!
0 · Reply
wemmmm
wemmmm Jun. 25 at 6:34 PM
$ABEO https://x.com/oraclenyse/status/1937940803323617746?s=46&t=PEWZbEPDlfCXIpORNZ-ynQ
0 · Reply
Paradise27
Paradise27 Jun. 25 at 5:54 PM
$ABEO Golden Cross on the chart bodes well for reversal to upward trend. MACD also rising with positive cross over most likely early next week. Buying pressure will build as ABEO heads towards profitability. Possible good news lurking from company near term. Shorts are done here.
0 · Reply
SeeKingProphet
SeeKingProphet Jun. 25 at 3:14 PM
$ABEO recent bear article from Sage Advisors being challenged by article in The Tencent is a buy signal IMHO. Whopping 9 days to cover could result in a squeeze soon 🌋
1 · Reply
creditgoo
creditgoo Jun. 25 at 2:41 PM
$ABEO interesting candle
0 · Reply
xelaxela
xelaxela Jun. 25 at 2:40 PM
$ABEO huge green candle!
0 · Reply
alexpitti
alexpitti Jun. 25 at 1:56 PM
$ABEO will be manipulation until sales start. Q2 report in August should be the start of the rally
1 · Reply
JimiJoJeeter
JimiJoJeeter Jun. 25 at 1:49 PM
$ABEO Seems to me that the crooks with algos are playing a long game of holding it down till they drive out the greatest number of weak hands.... High speed machine trading should be illegal. Only humans should be allowed to place trades.....
0 · Reply
creditgoo
creditgoo Jun. 25 at 1:45 PM
$ABEO told you this was headimg back to 4s
1 · Reply
Tjcmd
Tjcmd Jun. 25 at 5:05 AM
$ABEO In case anyone missed this before…
0 · Reply
alexpitti
alexpitti Jun. 24 at 4:38 PM
The bear article on $ABEO twisted logic. It was baseless. Biased. Just terrible work.
0 · Reply
Filipvul
Filipvul Jun. 24 at 3:46 PM
0 · Reply
DonCorleone77
DonCorleone77 Jun. 24 at 11:38 AM
$ABEO Abeona Therapeutics announces publication in The Lancet of Phase 3 VITAL study Abeona Therapeutics announced that The Lancet has published results from the pivotal Phase 3 VIITAL study evaluating the efficacy and safety of ZEVASKYN gene-modified cellular sheets, also known as pz-cel, for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, RDEB. This article, titled, "Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa Wounds: A Two-Centre, Randomised, Open-Label, Intrapatient-Controlled Phase 3 Trial," representing the primary publication of the full VIITAL study data, is now available online and will be published in a future print issue of The Lancet. ZEVASKYN demonstrated significant wound healing and pain reduction after a single treatment with a favorable safety profile in large chronic RDEB wounds.
0 · Reply
JBio
JBio Jun. 24 at 10:32 AM
$ABEO https://lpfch.org/impact-stories/donor-support-advances-new-treatment-for-eb-a-rare-and-painful-skin-disease/ Twenty-year-old Charlotte Brown of Birmingham, Alabama, experiences much less pain from EB than before she joined the phase 3 trial in 2021. The genetically engineered grafts she received in the trial have greatly reduced the severity of several chronic wounds. She is even able to hold down a job she loves—as a pharmacy technician. “It’s honestly life-changing,” Brown says. “I feel so much better.”
0 · Reply
xelaxela
xelaxela Jun. 23 at 4:34 PM
$ABEO hmm why?
0 · Reply
alexpitti
alexpitti Jun. 20 at 8:39 PM
Easily one of my worst days ever. Absolutely no news. Just pummeled $STXS down 10% $MYO down 11% $DCTH down 2% (24% off the high) $ABEO down 2% (down 13% from June 6)
6 · Reply
RDeneronow
RDeneronow Jun. 20 at 2:17 PM
0 · Reply
xelaxela
xelaxela Jun. 20 at 1:45 PM
$ABEO The next news report will be wrapping up the sale of the PRV. Which should be in the next few days or late next week.
0 · Reply